Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis

Document Type

Article

Abstract

Amyotrophic lateral sclerosis (ALS) is characterized by degeneration of motor neurons. We tested the hypothesis that proteomic analysis will identify protein biomarkers that provide insight into disease pathogenesis and are diagnostically useful. To identify ALS specific biomarkers, we compared the proteomic profile of cerebrospinal fluid (CSF) from ALS and control subjects using surface-enhanced laser desorption/ ionization-time of flight mass spectrometry (SELDI-TOF-MS). We identified 30 mass ion peaks with statistically significant (p < 0.01) differences between control and ALS subjects. Initial analysis with a rule-learning algorithm yielded biomarker panels with diagnostic predictive value as subsequently assessed using an independent set of coded test subjects. Three biomarkers were identified that are either decreased (transthyretin, cystatin C) or increased (carboxy-terminal fragment of neuroendocrine protein 7B2) in ALS CSF. We validated the SELDI-TOF-MS results for transthyretin and cystatin C by immunoblot and immunohistochemistry using commercially available antibodies. These findings identify a panel of CSF protein biomarkers for ALS. © 2005 International Society for Neurochemistry.

Keywords

Amyotrophic lateral sclerosis, Cerebrospinal fluid, Mass spectrometry, Proteomics

Publication Date

12-1-2005

Publication Title

Journal of Neurochemistry

ISSN

00223042

Volume

95

Issue

5

First Page

1461

Last Page

1471

PubMed ID

16313519

Digital Object Identifier (DOI)

10.1111/j.1471-4159.2005.03478.x

This document is currently not available here.

Share

COinS